PRESTIGE CONSUMER HEALTHCARE INC. Treasury Stock, Shares, Acquired
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, shares, acquired for the quarter ending 2019-12-31 was 0.00 shares.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, shares, acquired for the quarter ending 2019-09-30 was 672.72K shares.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, shares, acquired for the quarter ending 2019-06-30 was 949.83K shares, a 34.48% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, shares, acquired for the quarter ending 2019-03-31 was 0.00 shares.
- PRESTIGE CONSUMER HEALTHCARE INC. treasury stock, shares, acquired for fiscal 2019 was 1.45M shares.
| Period end | Treasury Stock, Shares, Acquired 3 month | Treasury Stock, Shares, Acquired 12 month |
|---|---|---|
| 2019-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-06 | 1.62M shares derived: sum of 4 quarters · filed 2020-02-06 |
| 2019-09-30 | 672.72K shares 10-Q · filed 2019-10-31 | 1.62M shares derived: sum of 4 quarters · filed 2020-02-06 |
| 2019-06-30 | 949.83K shares 10-Q · filed 2019-08-01 | 949.83K shares derived: sum of 4 quarters · filed 2020-02-06 |
| 2019-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-05-13 | 1.45M shares 10-K · filed 2019-05-13 |
| 2018-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-06 | |
| 2018-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-10-31 | |
| 2018-06-30 | 1.45M shares 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |